Humira HS Dosing: Weekly Regimens and Dose Escalation

Adalimumab, sold as Humira, is dosed more aggressively for hidradenitis suppurativa than for most other conditions it treats. The approved adult regimen starts with a loading dose of 160 mg on day one, followed by 80 mg two weeks later, then 40 mg injected subcutaneously every week from week four onward. That weekly maintenance schedule is notably higher than the every-other-week dosing used for conditions like psoriasis or rheumatoid arthritis, and the distinction matters for how well the drug controls HS flares over time.

Why HS Requires Weekly Dosing

HS is a deeply inflammatory disease driven largely by overproduction of tumor necrosis factor-alpha (TNF-α) and related cytokines in the skin. Adalimumab works by blocking TNF-α, and studies of HS skin biopsies show that treatment reduces the output of several inflammatory signaling molecules, including IL-1β and CXCL9.¹ But HS tends to burn through adalimumab faster than other inflammatory conditions do. Pharmacokinetic modeling has shown that the drug levels HS patients achieve on weekly 40 mg dosing are roughly in line with what patients on approved regimens for other indications achieve at lower frequencies.² In other words, the weekly schedule isn’t an unusually high dose for its effect on the body; it’s what HS patients need to reach the same therapeutic window that other patients hit with less frequent injections.

The phase 3 PIONEER I and II trials cemented this schedule. Patients who stayed on weekly dosing through 36 weeks had considerably better outcomes than those switched to every-other-week dosing or placebo after the initial 12-week period. About 43% of patients who continued weekly dosing achieved a meaningful clinical response at week 36, compared with roughly 31% on every-other-week dosing and 28% on placebo.³ The patients who dropped from weekly to less frequent dosing also experienced a larger increase in abscess and nodule counts, reinforcing that the disease tends to bounce back without consistent suppression.

Flares on Treatment and What to Expect

Even on the weekly schedule, flares happen. In the PIONEER trials, about 12% of patients on weekly adalimumab experienced a flare during the first 12 weeks, compared with 35% on placebo. The time to a first flare was also longer on the drug, averaging about 101 days versus 57 days on placebo, and when flares did occur they resolved faster. Among patients who had at least a partial response by week 12, fewer than 6% flared over the full 36-week treatment period.⁴

In longer-term real-world follow-up, the picture is a bit grittier. One observational study found that 90% of patients experienced at least one flare over their course of treatment, with an average gap between flares of about 27 weeks. The encouraging part was that flares became less frequent over time, and the proportion of patients achieving clinical response gradually climbed the longer they stayed on therapy.⁵ So while adalimumab doesn’t eliminate disease activity for most people, it tends to bend the curve over time. This is worth knowing because many patients expect dramatic clearing within the first month, and the reality is usually a gradual improvement punctuated by setbacks.

When Standard Dosing Isn’t Enough

A meaningful chunk of HS patients don’t respond adequately to 40 mg weekly. For these cases, some dermatologists escalate to 80 mg weekly, doubling the maintenance dose. A study of patients with recalcitrant HS found that this intensification significantly improved disease scores, pain, and quality of life.⁶ Most patients in that cohort saw enhanced effectiveness at the higher dose, though two younger patients with concurrent Crohn’s disease developed psoriatic skin lesions during 80 mg/week treatment. Dose escalation to this level remains off-label and is typically a decision made after the standard regimen has been given a fair trial of several months.

Before jumping to a higher dose, it helps to understand why a patient isn’t responding. That’s where therapeutic drug monitoring comes in.

Therapeutic Drug Monitoring

Drug levels matter. Not all patients metabolize adalimumab the same way, and blood trough concentrations can vary widely. One retrospective case series of 38 patients with suboptimal response found a median trough level of about 8.8 µg/mL, with individual values ranging from near-undetectable to above 12.⁷ A more recent study used a therapeutic threshold of 10.6 µg/mL and classified patients below that as subtherapeutic.⁸

If your levels are below the target, the question becomes why. Two main explanations exist. The first is straightforward pharmacokinetics: your body clears the drug faster than average, often related to higher body weight, higher inflammatory burden, or both. In that case, dose escalation can help. The second explanation is immunogenicity, where your immune system makes antibodies against adalimumab itself, neutralizing the drug before it can work. Patients who develop these antidrug antibodies are more than twice as likely to discontinue treatment due to ineffectiveness.⁹ When antibodies are the problem, simply increasing the dose often won’t fix things. Switching to a different biologic is usually the better move.

Adolescent Dosing

In 2018, the FDA expanded adalimumab’s HS approval to adolescents aged 12 and older who weigh at least 30 kg. No new clinical trials were conducted in teens; instead, the approval relied on pharmacokinetic modeling that predicted weight-based dosing in adolescents would produce drug exposures similar to what adults achieve on the standard regimen.¹⁰ For adolescents weighing 60 kg or more, the dosing is identical to adults. For those between 30 and 60 kg, the loading and maintenance doses are halved.

Real-world data, however, suggests the lower adolescent dosing schedule may be insufficient for many teens. A multicenter case series found that about 77% of adolescents achieved clinical response at six months, which sounds good. But when the researchers looked at who needed dose intensification during treatment, the story shifted. Among patients started on the lower adolescent schedule (40 mg every other week), over 70% needed to be bumped up to a higher dose. Among those started on adult-level dosing from the outset, only about 15% needed intensification. The odds of needing a dose increase were dramatically higher on the adolescent schedule, and that association held regardless of whether the patient was younger or older than 15.¹¹ This has pushed many dermatologists toward starting heavier adolescents directly on adult dosing.

Combining Adalimumab With Antibiotics

Clindamycin and rifampicin, a classic antibiotic combination used in HS, appears to boost adalimumab’s effectiveness when the two are started together. A study comparing patients who initiated adalimumab alongside this antibiotic duo versus adalimumab alone found that the combination group had substantially better disease score improvement, with more than double the rate of meaningful disease control at the measured time point. Draining tunnels, one of the most debilitating features of HS, also reduced more in the combination group, and pain response was notably better.¹² The antibiotics are typically used for a limited course (often 10 to 12 weeks) to knock down infection and inflammation at the start of biologic therapy, then discontinued while adalimumab continues.

One practical wrinkle: rifampicin can speed up drug metabolism through liver enzyme induction, which theoretically could lower adalimumab levels. Most clinicians feel comfortable using the combination for a short course, but the interaction is something your prescriber should have on their radar.

Adalimumab Around Surgery

Many HS patients end up needing surgery, especially for chronic tunneling lesions and recurrent abscesses. A reasonable worry is whether being on an immune-suppressing biologic during surgery increases the risk of wound complications. The evidence is reassuring. A study looking at wound healing after HS surgery found that continuing adalimumab through the perioperative period did not increase postoperative complications or slow down wound closure.¹³ The SHARPS randomized trial went further, demonstrating that adalimumab was effective when used alongside wide-excision surgery with secondary intention healing, and confirmed there was no need to interrupt treatment before operating.¹⁴

This is good news for patients and surgeons alike, because stopping a biologic before surgery risks a disease flare at the worst possible time. The current weight of evidence supports continuing adalimumab through an HS surgical procedure.

Long-Term Safety

Three-year data from the open-label extension of the PIONEER trials found that the safety profile of long-term weekly adalimumab remained consistent with what was seen in the initial 12-week studies, with no new safety signals emerging.¹⁵ The well-known risks of TNF-α blockers, including increased susceptibility to certain infections and a theoretical concern about malignancy with long-term use, apply to HS patients just as they do to anyone else on these drugs. Routine monitoring with periodic bloodwork and attention to infection symptoms is standard practice.

Switching to Biosimilar Adalimumab

With the arrival of adalimumab biosimilars (Hadlima, Hyrimoz, Cyltezo, and others), many patients have been switched from originator Humira for cost reasons. Whether this matters for HS outcomes is an active area of debate. One early review found no significant differences in clinical response when patients switched from originator to biosimilar adalimumab.¹⁶

A more recent multicenter real-world analysis tells a less comfortable story. That study found the median time to loss of response was 87 weeks on originator adalimumab versus 50 weeks on biosimilar adalimumab after switching, with patients on the biosimilar facing roughly 2.4 times the hazard of losing response at any given time. Even after adjusting for BMI and disease severity, switching to biosimilar was associated with about a 181% increase in the odds of losing clinical response.¹⁷ This is a single observational study and far from the final word, but it’s worth discussing with your dermatologist if you’re being transitioned. The mechanism could involve subtle formulation differences, nocebo effects (loss of confidence after switching), or unmeasured confounders. More data from larger registries will eventually clarify whether this signal holds up.

Injection Formulation and Sticking With Treatment

Adalimumab was originally manufactured in a citrate buffer that made injections sting. A citrate-free formulation was introduced to reduce injection-site pain. Beyond comfort, the formulation change appears to affect whether patients keep up with treatment. A large claims-based analysis across immune-mediated diseases found that patients on the citrate-free version had meaningfully higher adherence, with a greater proportion staying above the 80% compliance threshold and a 27% lower likelihood of discontinuing treatment over a year.¹⁸ If you’re on a biosimilar that uses the older citrate formulation and finding injections painful, that’s worth raising with your provider, because pain-related non-adherence can quietly erode the drug’s effectiveness.

How Adalimumab Compares to Newer HS Biologics

Adalimumab was the first biologic approved for HS and remained the only one for years. Now it faces competition from secukinumab (an IL-17A blocker) and bimekizumab (a dual IL-17A/IL-17F blocker), both of which have completed phase 3 trials. A network meta-analysis pooling data from the PIONEER, SUNSHINE, SUNRISE, and BE HEARD trials (over 2,700 patients combined) ranked adalimumab weekly as the most effective option for reaching a meaningful clinical response threshold. It showed significant superiority over secukinumab at both tested dosing intervals and had a numerical but not statistically significant edge over bimekizumab.¹⁹

That ranking comes with caveats. Network meta-analyses compare trials indirectly rather than pitting drugs against each other in the same study, and patient populations across trials aren’t perfectly matched. Head-to-head data between adalimumab and bimekizumab would be more definitive and may eventually arrive. For now, adalimumab’s long track record, relatively well-understood dosing landscape, and the availability of cheaper biosimilars give it practical advantages even if a newer agent turns out to be modestly more effective in direct comparison. The choice often comes down to individual response, insurance coverage, and your physician’s experience with each drug.

The Practicalities of Weekly Self-Injection

One underappreciated aspect of HS dosing is the sheer frequency of it. Weekly subcutaneous injections are a bigger commitment than what most biologic-treated patients in other conditions deal with. Common injection sites include the thigh and abdomen (avoiding the area directly around the navel). Rotating sites helps prevent lipodystrophy, where the fat layer under the skin thins or thickens from repeated injections in the same spot. Patients with active HS lesions in the abdominal fold or groin need to be careful about injecting too close to inflamed areas, both because absorption can be unpredictable in damaged tissue and because introducing a needle near an active abscess increases infection risk.

Keeping the drug properly refrigerated matters as well. Adalimumab that has been left at room temperature for more than 14 days should not be used. Many patients find it helpful to take the pen or syringe out of the fridge about 15 to 30 minutes before injecting, since cold medication can make the injection more uncomfortable. A consistent day and time each week can help build the habit, and many specialty pharmacies offer app-based reminders as part of their patient support programs.